Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)

Sairah Ahmed, Hongli Li, Alex F. Herrera, Anamarija M Perry, Alexandra E Kovach, Sarah C. Rutherford, Kelly Davison, Sharon M Castellino, Andrew M Evens, Brad S Kahl, Nancy Bartlett, John P Leonard, Margaret A. Shipp, Sonali M Smith, Kara M Kelly, Michael L LeBlanc, Jonathan W Friedberg, Joo Y. Y Song

Open source

DOI: 10.1182/bloodadvances.2026021402
Published: 2026-07-29
Container: Blood Advances
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2026021402,
  title = {Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)},
  author = {Sairah Ahmed and Hongli Li and Alex F. Herrera and Anamarija M Perry and Alexandra E Kovach and Sarah C. Rutherford and Kelly Davison and Sharon M Castellino and Andrew M Evens and Brad S Kahl and Nancy Bartlett and John P Leonard and Margaret A. Shipp and Sonali M Smith and Kara M Kelly and Michael L LeBlanc and Jonathan W Friedberg and Joo Y. Y Song},
  year = {2026},
  journal = {Blood Advances},
  doi = {10.1182/bloodadvances.2026021402},
  url = {https://doi.org/10.1182/bloodadvances.2026021402}
}

RIS

TY  - JOUR
TI  - Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)
AU  - Sairah Ahmed
AU  - Hongli Li
AU  - Alex F. Herrera
AU  - Anamarija M Perry
AU  - Alexandra E Kovach
AU  - Sarah C. Rutherford
AU  - Kelly Davison
AU  - Sharon M Castellino
AU  - Andrew M Evens
AU  - Brad S Kahl
AU  - Nancy Bartlett
AU  - John P Leonard
AU  - Margaret A. Shipp
AU  - Sonali M Smith
AU  - Kara M Kelly
AU  - Michael L LeBlanc
AU  - Jonathan W Friedberg
AU  - Joo Y. Y Song
PY  - 2026
JO  - Blood Advances
DO  - 10.1182/bloodadvances.2026021402
UR  - https://doi.org/10.1182/bloodadvances.2026021402
ER  -

APA

Ahmed, S., Li, H., Herrera, A. F., Perry, A. M., Kovach, A. E., Rutherford, S. C., Davison, K., Castellino, S. M., Evens, A. M., Kahl, B. S., Bartlett, N., Leonard, J. P., Shipp, M. A., Smith, S. M., Kelly, K. M., LeBlanc, M. L., Friedberg, J. W., & Song, J. Y. Y. (2026). Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826). Blood Advances. https://doi.org/10.1182/bloodadvances.2026021402

Source records

crossref · retrieved 2026-09-26T20:00:04.574Z